Novartis Pharma

Novartis receives E.C. approval for once-daily Seebri Breezhaler for COPD

Monday, October 1, 2012 12:11 PM

The European Commission has approved Novartis’ Seebri Breezhaler (glycopyrronium bromide) 44µg delivered dose, as a once-daily inhaled maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

More... »

FDA approves first drug formulated for children with rare brain tumor

Monday, September 3, 2012 08:25 AM

The FDA has approved Novartis’ Afinitor Disperz (everolimus tablets for oral suspension), a new pediatric dosage form of the anti-cancer drug Afinitor used to treat subependymal giant cell astrocytoma (SEGA, a rare brain tumor).

More... »

Sosei, Novartis tout positive results for phase III QVA149 study in COPD

Thursday, August 30, 2012 03:19 PM

Novartis and Sosei Group, an international biopharmaceutical company based in Japan, released results from the fifth QVA149 (indacaterol maleate / glycopyrronium bromide) phase III study, SPARK, which met its primary endpoint of a reduced rate of moderate-to-severe COPD exacerbations compared to glycopyrronium bromide (Seebri Breezhaler).

More... »

Endocyte appoints Novartis vet David Meek as chief commercial officer

Monday, July 30, 2012 03:49 PM

Endocyte, an Indianapolis, Ind.-based biopharmaceutical company focused on cancer and inflammatory diseases, has appointed David Meek to the newly created position of chief commercial officer. He will be responsible for the development of Endocyte’s commercial team and overall commercial strategy and execution.

More... »

Novartis’ Gilenya earns positive results in extended phase III head-to-head study

Monday, June 11, 2012 02:52 PM

New long-term data for Gilenya (fingolimod), the only oral therapy approved to treat people with relapsing forms of multiple sclerosis (MS), show a sustained efficacy benefit and a consistent safety profile with up to 4.5 years of continuous treatment, according to Switzerland-based Novartis Pharma.

More... »

Creabilis appoints Simon Russell as chief business officer

Friday, May 4, 2012 04:43 PM

Creabilis, a European biotech specializing in the development of treatments for dermatology, inflammation and pain, has appointed Simon Russell as chief business officer.

More... »

Novartis phase III COPD studies meet primary endpoints

Friday, April 6, 2012 03:08 PM

The first three Novartis Pharmaceuticals QVA149 phase III studies in the treatment of chronic obstructive pulmonary disease (COPD) all met their primary endpoints.

More... »

Dr. Stephen Chen named chairman, CEO of Amarillo

Monday, February 27, 2012 10:10 AM

Amarillo Biosciences, a U.S. biotechnology firm, has appointed Dr. Stephen T. Chen CEO and chairman of the board.

More... »

J&J’s Alex Gorsky succeeds Bill Weldon as CEO

Saturday, February 25, 2012 06:34 AM

Johnson & Johnson’s board of directors has named Alex Gorsky CEO of J&J effective April 26, 2012, the date of the company’s annual meeting of shareholders.  

More... »

Novartis wins PharmaTimes Clinical Company of the Year

Friday, February 24, 2012 10:48 AM

Novartis Pharmaceuticals won of the overall prize for PharmaTimes Clinical Company of the Year at an awards ceremony in London on February16.

More... »